Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL

PURPOSE: Histone deacetylase inhibitors (HDACi) have recently emerged as efficacious therapies that target epigenetic mechanisms in hematologic malignancies. One such hematologic malignancy, B-cell acute lymphoblastic leukemia (B-ALL), may be highly dependent on epigenetic regulation for leukemia de...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Stubbs, Matthew C., Kim, Wonil, Bariteau, Megan, Davis, Tina, Vempati, Sridhar, Minehart, Janna, Witkin, Matthew, Qi, Jun, Krivtsov, Andrei V., Bradner, James E., Kung, Andrew L., Armstrong, Scott A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4433811/
https://ncbi.nlm.nih.gov/pubmed/25688158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1290
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados